Classification of colon cancer patients into consensus molecular subtypes using support vector machines
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study developed an RNA-seq gene classifier for colon cancer molecular subtypes. The optimized 25-gene classifier achieved high specificity for Consensus Molecular Subtypes (CMS), aiding personalized treatment strategies.
Area Of Science
- Oncology
- Genomics
- Bioinformatics
Background
- Colon cancer exhibits molecular heterogeneity, necessitating accurate tumor classification for effective treatment.
- The Consensus Molecular Subtypes (CMS) framework provides a molecular subtyping approach for colon cancer.
- Current RNA-sequencing (RNA-Seq) based CMS classification methods show limitations in sensitivity and specificity.
Purpose Of The Study
- To develop and optimize an RNA-Seq-based gene classifier for molecular subtyping of colon cancer patients into CMS groups.
- To identify subtype-specific and survival-associated genes for improved classification accuracy.
Main Methods
- Subtype-specific and survival-associated genes were identified using the Fuzzy C-Means algorithm and log-rank test.
- Patient classification into CMS groups was performed using support vector machines with backward elimination.
- Optimization of the RNA-Seq-based classifier involved selecting 25 genes to minimize classification error.
Main Results
- An optimized 25-gene signature was identified for colon cancer classification with minimal error rates.
- Classification performance was evaluated using metrics including precision, sensitivity, specificity, false discovery rate, and balanced accuracy.
- CMS3-associated genes demonstrated the highest specificity but lowest sensitivity, attributed to a small patient cohort for this subtype.
Conclusions
- A gene list for colon cancer classification with minimized error rates has been established.
- The developed classifier shows promise for improving the accuracy of molecular subtyping in colon cancer.
- Further validation is warranted, particularly for subtypes with limited patient representation in the current study.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.